Imaging Technology

JANUARY 12, 2024

“We are grateful that CMS recognizes the potential of our SCINTIX therapy for patients with all stages of indicated cancers and, with this decision, has addressed provider payment as a barrier to clinical adoption,” continued Powell. Patient treatments also began at several clinical sites in 2023. 1, 2024, to describe SCINTIX therapy.

Radiopharmaceuticals 100

Radiopharmaceuticals Radiation Medicare Clinic 100

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 95

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 95

AuntMinnie

MARCH 25, 2024

PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. Coronary artery disease (CAD) is the leading cause of mortality in the U.S. The game-changer could be the pending U.S.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

Imaging Technology

JULY 28, 2023

We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. FDA, as well as on the Phase 3 clinical trial results published recently in the Journal of Urology and European Urology. Chief Executive Officer of the Company. “We

Clinic 84

Clinic Diagnostic Radiopharmaceuticals Radiation 84

Imaging Technology

AUGUST 23, 2023

SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion. “We founder and CTO of RefleXion.“We

Radiopharmaceuticals 86

Radiopharmaceuticals Disease Radiation Clinic 86

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 63

Medical Radiopharmaceuticals Pharmaceutical Radiation 63

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 86

Nuclear Medicine Radiation Oncology Nursing Radiation 86

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.

Diagnostic 75

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 75

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 89

Radiopharmaceuticals Imaging Pharmaceutical Disease 89

Imaging Technology

JULY 11, 2023

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By RTX-1363S has the potential to transform the way we detect and monitor various epithelial-derived cancers." "We

Radiopharmaceuticals 70

Radiopharmaceuticals Imaging Pharmaceutical Disease 70

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.

Clinic 82

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 82

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 82

Medical Radiopharmaceuticals Pharmaceutical Radiation 82

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.

Diagnostic 92

Diagnostic Radiopharmaceuticals Imaging Radiation 92